Pooja Ghatalia, MD

Pooja Ghatalia, MD, of Fox Chase Cancer Center

Articles by Pooja Ghatalia, MD

RETAIN-2: Risk-Enabled Therapy After Neoadjuvant Chemo-Immunotherapy for MIBC

Pooja Ghatalia, MDMuscle Invasive Urothelial Carcinoma | February 20, 2025

Drs. Ghatalia and Nizam break down in detail the RETAIN-2 study, a phase 2 trial of risk enabled therapy for MIBC.